<HTML xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en" dir="ltr">
<style type="text/css">
A:before { content:' '; } 
A:after { content:' '; } 
SPAN:before { content:' '; } 
SPAN:after { content:' '; } 
</style>
<BODY class="mediawiki  ltr ns-0 ns-subject page-Team_Freiburg_Bioware_Project_Results_Arming"><DIV id="globalWrapper"><DIV id="top-section"><DIV id="p-logo"><A href="/Main_Page" title="Main Page">&quot;
	    </A></DIV><DIV id="menubar" class="left-menu noprint"><UL><LI class="selected"><A href="/Team:Freiburg_Bioware/Project/Results/Arming">Page               </A></LI><LI class="new"><A href="/wiki/index.php?title=Talk:Team:Freiburg_Bioware/Project/Results/Arming&amp;action=edit&amp;redlink=1">Discussion               </A></LI><LI><A href="/wiki/index.php?title=Team:Freiburg_Bioware/Project/Results/Arming&amp;action=edit">View source               </A></LI><LI><A href="/wiki/index.php?title=Team:Freiburg_Bioware/Project/Results/Arming&amp;action=history">History               </A></LI><LI style="color:#808080;cursor:default">teams</LI></UL></DIV><DIV class="right-menu noprint" id="menubar"><UL><LI id="pt-login"><A href="/wiki/index.php?title=Special:UserLogin&amp;returnto=Team:Freiburg_Bioware/Project/Results/Arming" title="You are encouraged to log in; however, it is not mandatory [o]" accesskey="o">Log in</A></LI></UL></DIV><DIV id="search-controls" class="noprint"><FORM action="/Special:Search" id="searchform"> </FORM></DIV></DIV><DIV id="content"><H1 class="firstHeading">Team:Freiburg Bioware/Project/Results/Arming</H1><DIV id="bodyContent"><H3 id="siteSub" class="noprint">From 2010.igem.org</H3><DIV id="menu"><UL id="menu"><LI><DL><DT class="menu_button_left"><A href="https://2010.igem.org/Team:Freiburg_Bioware">Home</A></DT></DL></LI><LI><DL><DT class="menu_button_center"><A href="https://2010.igem.org/Team:Freiburg_Bioware/Team/Team_2010">Team</A></DT><DD class="first"><A href="https://2010.igem.org/Team:Freiburg_Bioware/Team/Team_2010">Team 2010</A></DD><DD><A href="https://2010.igem.org/Team:Freiburg_Bioware/Team/Collaboration">Collaboration</A></DD><DD><A href="https://2010.igem.org/Team:Freiburg_Bioware/Team/Cuckoo_Clock">Cuckoo Clock Competition</A></DD><DD><A href="https://2010.igem.org/Team:Freiburg_Bioware/Team/Photo_Gallery">Photo Gallery</A></DD><DD><A href="https://2010.igem.org/Team:Freiburg_Bioware/NoteBook/Statistics">Statistics</A></DD><DD><A href="https://2010.igem.org/Team:Freiburg_Bioware/Team/Contribution">Contribution</A></DD></DL></LI><LI><DL><DT class="menu_button_center"><A href="https://2010.igem.org/Team:Freiburg_Bioware/Project/Results#highlights">Project</A></DT><DD class="first"><A href="https://2010.igem.org/Team:Freiburg_Bioware/Project/Results">Summary</A></DD><DD><A href="https://2010.igem.org/Team:Freiburg_Bioware/Project/Results#highlights">Highlights</A></DD><DD><A href="https://2010.igem.org/Team:Freiburg_Bioware/Project/Project_Description">Introduction</A></DD><DD><A href="https://2010.igem.org/Team:Freiburg_Bioware/Project/Results">Results</A></DD><DD><A href="https://2010.igem.org/Team:Freiburg_Bioware/Project/Results#modularization">   Modularization</A></DD><DD><A href="https://2010.igem.org/Team:Freiburg_Bioware/Project/Results#targeting">   Targeting</A></DD><DD><A href="https://2010.igem.org/Team:Freiburg_Bioware/Project/Results#arming">   Arming</A></DD><DD><A href="https://2010.igem.org/Team:Freiburg_Bioware/Project/Results#superconstruct">   Tumor Killing</A></DD><DD><A href="https://2010.igem.org/Team:Freiburg_Bioware/Modeling">   Modeling</A></DD><DD><A href="https://2010.igem.org/Team:Freiburg_Bioware/Project/Methods">Methods</A></DD><DD><A href="https://2010.igem.org/Team:Freiburg_Bioware/Project/Virus_Construction_Kit">Virus Construction Kit Manual</A></DD></DL></LI><LI><DL><DT class="menu_button_center"><A href="https://2010.igem.org/Team:Freiburg_Bioware/BioBricks">BioBricks</A></DT><DD class="first"><A href="https://2010.igem.org/Team:Freiburg_Bioware/BioBricks">Overview</A></DD><DD><A href="https://2010.igem.org/Team:Freiburg_Bioware/BioBricks/capsid_coding">Capsid Coding Parts</A></DD><DD><A href="https://2010.igem.org/Team:Freiburg_Bioware/BioBricks/vector_plasmid">Vector Plasmid Parts</A></DD></DL></LI><LI><DL><DT class="menu_button_center"><A href="https://2010.igem.org/Team:Freiburg_Bioware/Notebook">Notebook</A></DT><DD class="first"><A href="https://2010.igem.org/Team:Freiburg_Bioware/NoteBook/Labjournal">Labjournal</A></DD><DD><A href="https://2010.igem.org/Team:Freiburg_Bioware/NoteBook/Materials">Cloning Material</A></DD><DD><A href="https://2010.igem.org/Team:Freiburg_Bioware/Project/Methods">Methods</A></DD><DD><A href="https://2010.igem.org/Team:Freiburg_Bioware/NoteBook/Meetings">Meetings</A></DD><DD><A href="https://2010.igem.org/Team:Freiburg_Bioware/NoteBook/Statistics">Statistics</A></DD></DL></LI><LI><DL><DT class="menu_button_center"><A href="https://2010.igem.org/Team:Freiburg_Bioware/Sponsors">Sponsors</A></DT></DL></LI><LI><DL><DT class="menu_button_center"><A href="https://2010.igem.org/Team:Freiburg_Bioware/Safety">Safety</A></DT></DL></LI><LI><DL><DT class="menu_button_right"><A href="https://2010.igem.org/Team:Freiburg_Bioware/Modeling">Modeling</A></DT><DD class="first"><A href="https://2010.igem.org/Team:Freiburg_Bioware/Modeling">Modeling Overview</A></DD><DD><A href="https://2010.igem.org/Team:Freiburg_Bioware/Modeling/Virus_Production">Virus Production</A></DD><DD><A href="https://2010.igem.org/Team:Freiburg_Bioware/Modeling/Virus_Infection">Virus Infection</A></DD><DD><A href="https://2010.igem.org/Team:Freiburg_Bioware/Modeling/Structure_Modeling">Structure Modeling</A></DD></DL></LI></UL></DIV><DIV class="pageContent"><P class="MsoTocHeading">Contents</P><P class="MsoToc2"><A href="#_Toc275981841"><SPAN lang="EN-US">Arming: Suicide
Genes as GOIs</SPAN><SPAN style="color: windowtext; display: none; text-decoration: none;">. </SPAN><SPAN style="color: windowtext; display: none; text-decoration: none;">1</SPAN></A></P><P class="MsoToc3"><A href="#_Toc275981842"><SPAN lang="EN-US">Introduction</SPAN><SPAN style="color: windowtext; display: none; text-decoration: none;">. </SPAN><SPAN style="color: windowtext; display: none; text-decoration: none;">1</SPAN></A></P><P class="MsoToc3"><A href="#_Toc275981843"><SPAN lang="EN-US">Successful Assembly
of Vector Plasmids Carrying Suicide Genes via Cloning</SPAN><SPAN style="color: windowtext; display: none; text-decoration: none;">. </SPAN><SPAN style="color: windowtext; display: none; text-decoration: none;">1</SPAN></A></P><P class="MsoToc3"><A href="#_Toc275981844"><SPAN lang="EN-US">Monitoring Efficient
Tumor Killing by Phase-Contrast Microscopy</SPAN><SPAN style="color: windowtext; display: none; text-decoration: none;">. </SPAN><SPAN style="color: windowtext; display: none; text-decoration: none;">4</SPAN></A></P><P class="MsoToc3"><A href="#_Toc275981845"><SPAN lang="EN-US">Quantitative
Analysis of Cell Death by Flow Cytometry</SPAN><SPAN style="color: windowtext; display: none; text-decoration: none;">. </SPAN><SPAN style="color: windowtext; display: none; text-decoration: none;">6</SPAN></A></P><P class="MsoToc3"><A href="#_Toc275981846"><SPAN lang="EN-US">Titrating
Ganciclovir Concentrations for Efficient Cell Killing by Cytotoxicity Assays</SPAN><SPAN style="color: windowtext; display: none; text-decoration: none;">. </SPAN><SPAN style="color: windowtext; display: none; text-decoration: none;">8</SPAN></A></P><P class="MsoToc3"><A href="#_Toc275981847"><SPAN lang="EN-US">Killing Untransduced
Tumor Cells via Bystander Effect</SPAN><SPAN style="color: windowtext; display: none; text-decoration: none;">13</SPAN></A></P><P class="MsoToc3"><A href="#_Toc275981848"><SPAN lang="EN-US">Conclusions</SPAN><SPAN style="color: windowtext; display: none; text-decoration: none;">. </SPAN><SPAN style="color: windowtext; display: none; text-decoration: none;">16</SPAN></A></P><P class="MsoToc3"><A href="#_Toc275981849"><SPAN lang="EN-US">References</SPAN><SPAN style="color: windowtext; display: none; text-decoration: none;">. </SPAN><SPAN style="color: windowtext; display: none; text-decoration: none;">16</SPAN></A></P><P class="MsoNormal"> </P><H2><A name="_Toc275981841"><SPAN lang="EN-US">Arming: Suicide Genes as GOIs</SPAN></A></H2><H3><A name="_Toc275981842"><SPAN lang="EN-US">Introduction</SPAN></A></H3><P class="MsoNormal"><SPAN lang="EN-US">Gene delivery using viral vectors to
specifically target tumor cells gained increasing attention in the last years
being efficient in combination with suicide gene approaches </SPAN><SPAN lang="EN-US">(Willmon et al. 2006)</SPAN><SPAN lang="EN-US">. Several prodrug/enzyme
combinations have been reported. Two systems - ganciclovir (GCV)/herpes simplex
virus thymidine kinase (HSV-TK) </SPAN><SPAN lang="EN-US">(Ardiani et al. 2010)</SPAN><SPAN lang="EN-US"> and
5-fluorocytosine/cytosine deaminase (CD) </SPAN><SPAN lang="EN-US">(Fuchita et al. 2009a)</SPAN><SPAN lang="EN-US"> – have been widely
used and their therapeutic benefit was demonstrated in preclinical studies </SPAN><SPAN lang="EN-US">(Greco &amp; Dachs 2001)</SPAN><SPAN lang="EN-US">. Adeno-associated
viruses (AAV) as delivery vectors are commonly used in suicide gene therapy. The
suicide gene flanked by the inverted terminal repeats (ITRs) is encapsulated into
the virus particles and delivered to the target cells where suicide gene
expression is mediated by cellular proteins.</SPAN></P><P class="MsoNormal"><SPAN lang="EN-US">The iGEM team Freiburg_Bioware 2010 provides
both the cytosine deaminase (CD,(<A href="http://partsregistry.org/Part:BBa_K404112" target="blank"> BBa_K404112</A>) and an improved guanylate kinase -
thymidine kinase fusion gene (mGMK_TK, (<A href="http://partsregistry.org/Part:BBa_K404113" target="blank"> BBa_K404113</A>) within the Virus
Construction Kit as effective suicide genes. We demonstrate efficient and
specific killing of tumor cells by enzymatic cytotoxicity assays, flow
cytometry, as well as phase contrast microscopy. HT1080 cancer cell lines were
transduced with directed viral particles containing the suicide genes packaged
into the viral capsids. </SPAN></P><H3><A name="_Toc275981843"><SPAN lang="EN-US">Successful Assembly of Vector Plasmids
Carrying Suicide Genes via Cloning</SPAN></A></H3><P class="MsoNormal"><SPAN lang="EN-US">To create the functional vector plasmids, assembly
of the constructs carrying the suicide genes was performed following the
BioBrick Standard Assembly. All plasmids contain the enhancer-element human <I>beta-globin</I>
intron (<A href="http://partsregistry.org/Part:BBa_K404107" target="blank"> BBa_K404107</A>) and the <I>human growth hormone</I> terminator signal (hGH,
<A href="http://partsregistry.org/Part:BBa_K404108" target="blank"> BBa_K404108</A>) flanked by the inverted terminal repeats (ITRs, <A href="http://partsregistry.org/Part:BBa_K404100" target="blank"> BBa_K404100</A> and
<A href="http://partsregistry.org/Part:BBa_K404101" target="blank"> BBa_K404101</A>). Assembled suicide genes are either under the control of the CMV
promoter (<A href="http://partsregistry.org/Part:BBa_J52034" target="blank"> BBa_J52034</A>) or the tumor-specific telomerase promoter phTERT (<A href="http://partsregistry.org/Part:BBa_K404106" target="blank"> BBa_K404106</A>).
</SPAN></P><DIV align="center"><TABLE class="MsoTableGrid" style="border: medium none ; border-collapse: collapse;" border="0" cellpadding="0" cellspacing="0"><TBODY><TR style="height: 343.9pt;"><TD style="padding: 0cm 5.4pt; width: 435.8pt; height: 343.9pt;" valign="top" width="581"><P class="MsoCaption"><A name="_Ref275976895"><SPAN lang="EN-US">Figure </SPAN></A><SPAN lang="EN-US">1</SPAN><SPAN lang="EN-US">: BioBrick-compatible assembly of functional
  vector plasmids containing the suicide genes. The schematic figure shows the
  cloning strategy of the guanylate kinase – thymidine kinase fusion gene
  (mGMK_TK30).</SPAN></P></TD></TR></TBODY></TABLE></DIV><P class="MsoNormal" style="text-indent: 0cm;"><SPAN lang="EN-US"> </SPAN></P><P class="MsoNormal"><SPAN lang="EN-US">To enable modularization of the thymidine
kinase mutants TK30 and SR39 (<A href="http://partsregistry.org/Part:BBa_K404109" target="blank"> BBa_K404109</A> and <A href="http://partsregistry.org/Part:BBa_K404110" target="blank"> BBa_K404110</A>) according to the
BioBrick standard, the fusion genes mGMK_TK30 and mGMK_SR39 (<A href="http://partsregistry.org/Part:BBa_K404113" target="blank"> BBa_K404113</A> and </SPAN><SPAN style="line-height: 200%; color: black;" lang="EN-US"><A href="http://partsregistry.org/Part:BBa_K404315" target="blank"> BBa_K404315</A></SPAN><SPAN lang="EN-US">) and CD (</SPAN><SPAN style="line-height: 200%; color: black;" lang="EN-US"><A href="http://partsregistry.org/Part:BBa_K404112" target="blank"> BBa_K404112</A></SPAN><SPAN lang="EN-US">) were modified using the QuikChange
Lightning Site-Directed Mutagenesis Kit (Stratagene) for deletion of iGEM RFC10
pre- and suffix restriction sites. </SPAN><SPAN lang="EN-US">Figure 1</SPAN><SPAN lang="EN-US"> demonstrates one example of
successful deletion of a PstI restriction site located within the mGMK_TK30
sequence at position 3109. A point mutation was introduced replacing the
nucleotide G by A, resulting in the deletion of the restriction site while
maintaining the encoded amino acid glutamine. Exchange of guanine to adenine
was confirmed by sequencing (</SPAN><SPAN lang="EN-US">Figure 2</SPAN><SPAN lang="EN-US">). </SPAN></P><DIV align="center"><TABLE class="MsoTableGrid" style="border: medium none ; width: 479.55pt; border-collapse: collapse;" border="0" cellpadding="0" cellspacing="0" width="639"><TBODY><TR style="height: 179.55pt;"><TD style="padding: 0cm 5.4pt; width: 479.55pt; height: 179.55pt;" valign="top" width="639"><P class="MsoCaption"><A name="_Ref275976917"><SPAN lang="EN-US">Figure </SPAN></A><SPAN lang="EN-US">2</SPAN><SPAN lang="EN-US">: Cytosine to guanine exchange by
  site-directed mutagenesis using QuikChange Lightning Kit provided by
  Stratagene was successful as demonstrated by (A) test digestion linearizing
  the plasmid with PstI and (B) by sequencing.</SPAN></P></TD></TR></TBODY></TABLE></DIV><P class="MsoNormal" style="text-indent: 0cm;"><SPAN lang="EN-US"> </SPAN></P><P class="MsoNormal"><SPAN lang="EN-US">Furthermore, assembly of BioBrick-compatible
vector plasmids was performed. An example for the last assembly step of
mGMK_TK30 and hGH_rITR is shown in </SPAN><SPAN lang="EN-US">Figure 3</SPAN><SPAN lang="EN-US">. The plasmids were digested with
both XbaI and PstI (New England Biolabs, Insert: <A href="http://partsregistry.org/Part:BBa_K404116" target="blank"> BBa_K404116</A>: hGH_rITR) or SpeI
and PstI (Vector) and loaded on an agarose gel. As demonstrated in the preparative
gel in </SPAN><SPAN lang="EN-US">Figure 3</SPAN><SPAN lang="EN-US">, the expected
bands were detected under UV light and the extracted, subsequently purified DNA
was successfully ligated and transformed into <I>E. coli</I>. Each assembly
step for producing the BioBricks was conducted following the iGEM BioBrick
standard.</SPAN></P><DIV align="center"><TABLE class="MsoTableGrid" style="border: medium none ; width: 387.35pt; border-collapse: collapse;" border="0" cellpadding="0" cellspacing="0" width="516"><TBODY><TR style="height: 125.95pt;"><TD style="padding: 0cm 5.4pt; width: 387.35pt; height: 125.95pt;" valign="top" width="516"><P class="MsoCaption"><A name="_Ref275976959"><SPAN lang="EN-US">Figure </SPAN></A><SPAN lang="EN-US">3</SPAN><SPAN lang="EN-US">: Assembly of mGMK_TK30 (vector molecule, in
  pSB1C3) and hGH-terminator_rightITR (insert molecule). The digested fragments
  were visualized under UV-light and correspond to the expected sizes.</SPAN></P></TD></TR></TBODY></TABLE></DIV><P class="MsoNormal" style="text-indent: 0cm;"><SPAN lang="EN-US"> </SPAN></P><H3><A name="_Toc275981844"><SPAN lang="EN-US">Monitoring Efficient Tumor Killing
by Phase-Contrast Microscopy</SPAN></A></H3><P class="MsoNormal"><SPAN lang="EN-US">Tumor cells, transduced with viral
particles encapsidating the effector constructs containing the mGMK_TK30 driven
by the CMV promoter, were cultured both in presence and absence of ganciclovir
(Roche). Morphological changes were monitored via phase-contrast microscopy for
48 hours post infection. As it can be seen in </SPAN><SPAN lang="EN-US">Figure 4</SPAN><SPAN lang="EN-US">, non-transduced tumor cells treated
with ganciclovir and transduced cells without ganciclovir did not show
significant cell ablation. In contrast, transduced cells expressing the
guanylate kinase - thymidine kinase fusion protein showed significant cell
death after incubation with ganciclovir for 48 hours post infection. </SPAN></P><TABLE class="MsoTableGrid" style="border: medium none ; width: 491pt; border-collapse: collapse;" border="0" cellpadding="0" cellspacing="0" width="655"><TBODY><TR style="height: 188.8pt;"><TD style="padding: 0cm 5.4pt; width: 247.35pt; height: 188.8pt;" width="330"><P class="MsoNoSpacing"><B><SPAN lang="EN-US">A</SPAN></B></P></TD><TD style="padding: 0cm 5.4pt; width: 243.65pt; height: 188.8pt;" width="325"><P class="MsoNoSpacing"><B><SPAN lang="EN-US">B</SPAN></B></P></TD></TR><TR style="height: 188.8pt;"><TD style="padding: 0cm 5.4pt; width: 247.35pt; height: 188.8pt;" width="330"><P class="MsoNoSpacing"><B><SPAN lang="EN-US">C</SPAN></B></P></TD><TD style="padding: 0cm 5.4pt; width: 243.65pt; height: 188.8pt;" width="325"><P class="MsoNoSpacing"><B><SPAN lang="EN-US">D</SPAN></B></P></TD></TR><TR style="height: 34.2pt;"><TD colspan="2" style="padding: 0cm 5.4pt; width: 491pt; height: 34.2pt;" width="655"><P class="MsoCaption"><A name="_Ref275976998"><SPAN lang="EN-US">Figure </SPAN></A><SPAN lang="EN-US">4</SPAN><SPAN lang="EN-US">: Qualitative analysis of cell death induced
  by conversion of ganciclovir to ganciclovir-triphosphate by virus-delivered
  guanylate - thymidine kinase (mGMK_TK30). A: Non-transduced HT1080 cells
  incubated in the presence of ganciclovir not exhibiting cell death. B: Untreated
  transduced HT1080 cells showing a high survival rate. C: HT1080 cells
  transduced with 300 µL viral particles and incubated with ganciclovir leading
  to tumor cell ablation. D: HT1080 cells transduced with 600 µL viral
  particles and incubated with ganciclovir leading to ablation of tumor cells. </SPAN></P></TD></TR></TBODY></TABLE><P class="MsoNormal"><SPAN lang="EN-US"> </SPAN></P><P class="MsoNormal"><SPAN lang="EN-US">Suicide gene therapy is based on the localized
conversion of non-toxic prodrugs to toxic substances </SPAN><SPAN lang="EN-US">(Greco &amp; Dachs 2001)</SPAN><SPAN lang="EN-US">, promoting cell
death in the tumor tissue (</SPAN><SPAN lang="EN-US">Figure 5</SPAN><SPAN lang="EN-US">). Directed gene delivery is achieved by using recombinant viral
vectors as provided by the iGEM team Freiburg_Bioware 2010 within the Virus
Construction Kit.</SPAN></P><TABLE class="MsoTableGrid" style="border: medium none ; border-collapse: collapse; margin-left: 4.8pt; margin-right: 4.8pt;" align="left" border="0" cellpadding="0" cellspacing="0"><TBODY><TR style="height: 174.85pt;"><TD style="padding: 0cm 5.4pt; width: 447.8pt; height: 174.85pt;" valign="top" width="597"><P class="MsoCaption"><A name="_Ref275977093"><SPAN lang="EN-US">Figure </SPAN></A><SPAN lang="EN-US">5</SPAN><SPAN lang="EN-US">: Overview of the suicide gene therapy
  approach. Non-toxic prodrugs are converted into toxic effector molecules
  leading to cell death of the tumor cells. </SPAN></P></TD></TR></TBODY></TABLE><P class="MsoNormal"><SPAN lang="EN-US">Non-transduced cells can survive in the
presence of ganciclovir since the prodrug is not toxic for these cells (</SPAN><SPAN lang="EN-US">Figure 4</SPAN><SPAN lang="EN-US">A). </SPAN>The demonstration that
transduced cells are viable in the absence of ganciclovir confirms that cell
killing is indeed induced by combination of the delivered thymidine kinase and
treatment with ganciclovir. Viral particles encapsidating the suicide construct
mGMK_TK30 are efficient in directed gene delivery, thus leading to cell death
of transduced cells due to overexpression of mGMK_TK30 and prodrug conversion. The
cell-toxic ganciclovir-triphosphate is incorporated into the<SPAN lang="EN-US">
nascent DNA chain leading to replication termination and finally resulting in
death of dividing cells. </SPAN></P><H3><A name="_Toc275981845"><SPAN lang="EN-US">Quantitative Analysis of Cell
Death by Flow Cytometry</SPAN></A></H3><P class="MsoNormal"><SPAN lang="EN-US">Quantitative analysis of the cytotoxic
effect induced by mGMK_TK30 was first conducted by flow cytometry analysis 72 hours
post transduction. HT1080 cells were stained with 7-AAD and Annexin V. 7-AAD intercalates
in double-stranded DNA after penetrating cell membranes of dead cells, whereas
Annexin V specifically binds phosphatidylserine which is only accessible during
apoptosis. </SPAN><SPAN lang="EN-US">Figure 6</SPAN><SPAN lang="EN-US"> demonstrates
the relation between cell death and ganciclovir concentration.</SPAN></P><DIV align="center"><TABLE class="MsoTableGrid" style="border: medium none ; width: 477.6pt; border-collapse: collapse;" border="0" cellpadding="0" cellspacing="0" width="637"><TBODY><TR style="height: 248.5pt;"><TD style="padding: 0cm 5.4pt; width: 235.8pt; height: 248.5pt;" valign="top" width="314"><P class="MsoCaption"> </P></TD></TR><TR style="height: 38pt;"><TD colspan="2" style="padding: 0cm 5.4pt; width: 477.6pt; height: 38pt;" valign="top" width="637"><P class="MsoCaption" style="text-indent: 0cm;"><A name="_Ref275977177"><SPAN lang="EN-US">Figure </SPAN></A><SPAN lang="EN-US">6</SPAN><SPAN lang="EN-US">: Flow
  cytometry data analysis. </SPAN><SPAN lang="EN-US">A: Gating non-transduced
  HT1080 cells (control). B: Non-transduced cells without staining plotted
  against 7-AAD. C: Gating non-transduced cells stained with 7-AAD. D:
  Non-transduced, 7-AAD-stained cells plotted against 7-AAD. E: Gating
  transduced cells (GOI: mGMK_TK30) treated with 485 µM ganciclovir. F: Gated,
  Annexin-V stained cells plotted against AnnV-2 Log.  G: Gated cells  plotted
  against 7-AAD H: Gated, 7-AAD and Annexin-V stained cells plotted against
  7-AAD and Annexin-V. Gate R19 comprised Annexin-V and 7-AAD positive cells.</SPAN></P></TD></TR></TBODY></TABLE></DIV><P class="MsoNormal" style="text-indent: 0cm;"><SPAN lang="EN-US"> </SPAN></P><P class="MsoNormal" style="text-align: center; text-indent: 0cm;" align="center"><SPAN lang="EN-US"> </SPAN></P><DIV align="center"><TABLE class="MsoTableGrid" style="border: medium none ; border-collapse: collapse;" border="0" cellpadding="0" cellspacing="0"><TBODY><TR><TD style="padding: 0cm 5.4pt; width: 460.6pt;" valign="top" width="614"><P class="MsoCaption"><A name="_Ref275977227"><SPAN lang="EN-US">Figure </SPAN></A><SPAN lang="EN-US">7</SPAN><SPAN lang="EN-US">: Quantification of flow cytometry data
  provided in </SPAN><SPAN lang="EN-US">Figure 6</SPAN><SPAN lang="EN-US">. With
  increasing ganciclovir concentration, the survival rate of cells decreases. 60
  % of HT1080 cells treated with 4.85 mM ganciclovir show tumor ablation,
  however even lower amounts of ganciclovir lead to significant cell death.</SPAN></P></TD></TR></TBODY></TABLE></DIV><P class="MsoNormal" style="text-align: center; text-indent: 0cm;" align="center"><SPAN lang="EN-US"> </SPAN></P><P class="MsoNormal"><SPAN lang="EN-US">The effect of different ganciclovir
concentrations on transduced HT1080 sarcoma cells was investigated.
Transduction was performed with recombinant viral particles encapsidating the
mGMK_TK30 prodrug gene. 72 hours post infection, cells were stained with 7-AAD
and Annexin V. As </SPAN><SPAN lang="EN-US">Figure 7</SPAN><SPAN lang="EN-US"> shows,
the fraction of killed transduced cells is proportional to the applied ganciclovir
concentration.</SPAN></P><H3><A name="_Toc275981846"><SPAN lang="EN-US">Titrating Ganciclovir
Concentrations for Efficient Cell Killing by Cytotoxicity Assays</SPAN></A></H3><P class="MsoNormal"><SPAN lang="EN-US">Further analysis of the cytotoxic effect
induced by thymidine kinase converting ganciclovir to the toxic anti-metabolite
has been performed using MTT assays. 3-(4,5-Dimethylthiazol-2-yl)-2,5diphenyltetrazolium
bromide), also known as MTT, is a yellow-colored tetrazole, which is reduced to
purple insoluble formazan in the presence of NADH and NADPH </SPAN><SPAN lang="EN-US">(Roche n.d.)</SPAN><SPAN lang="EN-US">. Colorimetric analysis can be
carried out via spectrometry. Different tumor cell lines, HT1080 and A431, were
transduced with the recombinant viruses carrying the linear DNA construct
coding for mGMK-TK30 regulated by the CMV promoter and subsequently treated
with ganciclovir. 48 and 72 hours post infection, cells were incubated with MTT
and fresh DMEM. After cell lysis by DMSO, absorbance of formazan at 570 nm was
quantified using a Tecan Sunrise plate reader. </SPAN></P><DIV align="center"><TABLE class="MsoTableGrid" style="border: medium none ; width: 451.05pt; border-collapse: collapse;" border="0" cellpadding="0" cellspacing="0" width="601"><TBODY><TR style="height: 176.7pt;"><TD style="padding: 0cm 5.4pt; width: 451.05pt; height: 176.7pt;" valign="top" width="601"><P class="MsoNormal" style="text-indent: 0cm;"><B><SPAN lang="EN-US">A</SPAN></B></P></TD></TR><TR style="height: 176.7pt;"><TD style="padding: 0cm 3.5pt; width: 451.05pt; height: 176.7pt;" valign="top" width="601"><P class="MsoNormal" style="text-indent: 0cm;"><B>B</B></P><P class="MsoCaption"><A name="_Ref275977309"><SPAN lang="EN-US">Figure </SPAN></A><SPAN lang="EN-US">8</SPAN><SPAN lang="EN-US">: Effect of ganciclovir on HT1080 cell survival
  72 hours post infection as (A) two dimensional plot of survival of cells and
  (B) three-dimensional plot of ganciclovir, virus particles and cell survival.</SPAN></P></TD></TR></TBODY></TABLE></DIV><P class="MsoNormal" style="text-indent: 0cm;"><SPAN style="font-size: 8pt; line-height: 200%;" lang="EN-US"> </SPAN></P><P class="MsoNormal" style="text-indent: 0cm;"><SPAN style="font-size: 8pt; line-height: 200%;" lang="EN-US"> </SPAN></P><P class="MsoNormal" style="text-indent: 0cm;"><SPAN style="font-size: 8pt; line-height: 200%;" lang="EN-US"> </SPAN></P><DIV align="center"><TABLE class="MsoTableGrid" style="border: medium none ; width: 415pt; border-collapse: collapse;" border="0" cellpadding="0" cellspacing="0" width="553"><TBODY><TR style="height: 176.7pt;"><TD style="padding: 0cm 5.4pt; width: 415pt; height: 176.7pt;" valign="top" width="553"><P class="MsoNormal" style="text-indent: 0cm;"><B><SPAN lang="EN-US">A </SPAN></B><SPAN lang="EN-US"> </SPAN></P></TD></TR><TR style="height: 176.7pt;"><TD style="padding: 0cm 5.4pt; width: 415pt; height: 176.7pt;" valign="top" width="553"><P class="MsoNormal" style="text-indent: 0cm;"><B>B</B></P><P class="MsoCaption"><A name="_Ref275977314"><SPAN lang="EN-US">Figure </SPAN></A><SPAN lang="EN-US">9</SPAN><SPAN lang="EN-US">: Effect of ganciclovir on HT1080 cell survival
  96 hours post infection. (A) two dimensional plot of cell survival  (B)
  three-dimensional plot of ganciclovir, virus particles and cell survival.</SPAN></P></TD></TR></TBODY></TABLE></DIV><P class="MsoNormal" style="text-indent: 0cm;"><SPAN style="font-size: 8pt; line-height: 200%;" lang="EN-US"> </SPAN></P><P class="MsoNormal"><SPAN lang="EN-US">Data of MTT assay quantification are shown
in </SPAN><SPAN lang="EN-US">Figure 8</SPAN><SPAN lang="EN-US"> and </SPAN><SPAN lang="EN-US">Figure 9</SPAN><SPAN lang="EN-US">. HT1080 cells were infected with
viral particles containing the mGMK_TK30 transgene.  72 h- and 96 h post
infection and addition of ganciclovir, cells were incubated with MTT. Changes
in absorbance were measured and survival of cells plotted against ganciclovir
concentration. </SPAN><SPAN lang="EN-US">Figure 8</SPAN><SPAN lang="EN-US">A
demonstrates the correlation between increasing ganciclovir concentrations and
percentage of cell survival. Furthermore, different virus particle
concentrations were used for transduction. </SPAN><SPAN lang="EN-US">Figure 8</SPAN><SPAN lang="EN-US">B shows that the highest amount of
viral particles combined with the highest ganciclovir concentration led to
significant HT1080 apoptosis 72 hours post transduction.</SPAN></P><P class="MsoNormal"><SPAN lang="EN-US">Additionally, 96 hours post infection cells
were incubated with MTT and absorbance was quantified via spectrometry (</SPAN><SPAN lang="EN-US">Figure 9</SPAN><SPAN lang="EN-US">). Again, survival of HT1080 cells
was plotted against increasing ganciclovir concentrations. </SPAN></P><H3><A name="_Toc275981847"><SPAN lang="EN-US">Killing Non-transduced Tumor Cells
via Bystander Effect</SPAN></A></H3><P class="MsoNormal"><SPAN lang="EN-US">The bystander effect was first reported by </SPAN><SPAN lang="EN-US">Moolten (1986)</SPAN><SPAN lang="EN-US"> showing that prodrug
convertase negative cells surrounded by suicide enzyme positive cells did not
survive prodrug treatment. Besides efficient killing of targeted tumor cells,
neighboring, non-transduced cells are killed as well, providing an important
effect in cancer treatment. Since 5-Fluorouracil is soluble and can diffuse
into adjacent cells </SPAN><SPAN lang="EN-US">(Huber et al. 1993)</SPAN><SPAN lang="EN-US">(Huber et al. 1994)</SPAN><SPAN lang="EN-US">, the bystander effect
was demonstrated using cytosine deaminase as gene of interest.</SPAN></P><P class="MsoNormal"><SPAN lang="EN-US"> </SPAN></P><DIV align="center"><TABLE class="MsoTableGrid" style="border: medium none ; border-collapse: collapse;" border="0" cellpadding="0" cellspacing="0"><TBODY><TR><TD style="padding: 0cm 5.4pt; width: 460.6pt;" valign="top" width="614"><P class="MsoCaption"><SPAN lang="EN-US">Figure </SPAN><SPAN lang="EN-US">10</SPAN><SPAN lang="EN-US">: Schematic overview of the Bystander
  effect.</SPAN></P></TD></TR></TBODY></TABLE></DIV><P class="MsoNormal"><SPAN lang="EN-US"> </SPAN></P><P class="MsoNormal"><SPAN lang="EN-US">The aim was to investigate if the modified
AAV-2 is able to kill tumor cells with the cytosine deaminase (CD) as gene of interest.
The viral particles were produced according to the standard protocol using the
following plasmids:</SPAN></P><P class="MsoListParagraphCxSpFirst" style="margin-left: 53.85pt; text-indent: -18pt;"><SPAN style="font-family: Symbol;">·<SPAN style="font-family: &quot;Times New Roman&quot;; font-style: normal; font-variant: normal; font-weight: normal; font-size: 7pt; line-height: normal; font-size-adjust: none; font-stretch: normal;">        </SPAN></SPAN>pHelper</P><P class="MsoListParagraphCxSpMiddle" style="margin-left: 53.85pt; text-indent: -18pt;"><SPAN style="font-family: Symbol;" lang="EN-US">·<SPAN style="font-family: &quot;Times New Roman&quot;; font-style: normal; font-variant: normal; font-weight: normal; font-size: 7pt; line-height: normal; font-size-adjust: none; font-stretch: normal;">        </SPAN></SPAN><SPAN lang="EN-US">Rep/Cap:
pSB1C3_001_[AAV2]-Rep-VP123(ViralBrick-587KO-empty)_p5-TATAless</SPAN></P><P class="MsoListParagraphCxSpLast" style="margin-left: 53.85pt; text-indent: -18pt;"><SPAN style="font-family: Symbol;" lang="EN-US">·<SPAN style="font-family: &quot;Times New Roman&quot;; font-style: normal; font-variant: normal; font-weight: normal; font-size: 7pt; line-height: normal; font-size-adjust: none; font-stretch: normal;">        </SPAN></SPAN><SPAN lang="EN-US">Gene of interest:
pSB1C3_[AAV2]-left-ITR_pCMV_betaglobin_CD_hGH_[AAV2]-right-ITR</SPAN></P><P class="MsoNormal"><SPAN lang="EN-US">90 % confluent HT1080 cells were transduced
in T75 flasks with 9 ml of viral stock. In parallel, another T75 flask was
transduced with a viral stock packaged with the mVenus coding sequence to
assess transgene expression.</SPAN></P><P class="MsoNormal"><SPAN lang="EN-US">24 hours before harvesting the
CD-transduced cells, two six well plates with 200.000 cells per well were
seeded. After 30 hours, mVenus expression was observed and the CD-transduced
HT1080 were harvested. To minimize the influence of viral particles in the
medium, the cells were washed four times with PBS. The cells were counted via a
Neubauer cell chamber and 100.000 cells per well of a six well plate were
seeded. Additionally, 100.000 of the CD-transduced cells were seeded onto previously
seeded untransduced HT1080.</SPAN></P><P class="MsoNormal"><SPAN lang="EN-US">The incubation with the prodrug
5-fluorocytosine (5-FC) was performed at a final concentration of 53 mM.
According to Fuchita <I>et al.,</I> this amount should be sufficient to show
the functionality of the CD </SPAN><SPAN lang="EN-US">(Fuchita et al. 2009b)</SPAN><SPAN lang="EN-US">. As demonstrated in </SPAN><SPAN lang="EN-US">Figure 11</SPAN><SPAN lang="EN-US">, cytotoxicity of 5-FC is
remarkable.</SPAN></P><DIV align="center"><TABLE class="MsoTableGrid" style="border: medium none ; border-collapse: collapse;" border="0" cellpadding="0" cellspacing="0"><TBODY><TR style="height: 351pt;"><TD style="padding: 0cm 5.4pt; width: 457.65pt; height: 351pt;" valign="top" width="610"><P class="MsoCaption" style="text-indent: 0cm;"><SPAN lang="EN-US">Figure </SPAN><SPAN lang="EN-US">11</SPAN><SPAN lang="EN-US">: </SPAN><SPAN style="font-weight: normal;" lang="EN-US">Transduction of HT1080 with cytosine deaminase-packed viral
  particles. 5-FC: 5-fluorocytosine (53 mM)</SPAN></P></TD></TR></TBODY></TABLE></DIV><P class="MsoNormal" style="text-indent: 0cm;"><SPAN lang="EN-US"> </SPAN></P><P class="MsoNormal"><SPAN lang="EN-US">After three days of incubation in 5-fluorocytosine,
the cells were washed, detached with Trypsin, centrifuged at 200 g for 5 min
followed by two washing steps with PBS and finally resuspended with 200 µl
DMEM. Living cells were then counted via Trypan blue staining.</SPAN></P><P class="MsoNormal"><SPAN lang="EN-US">After this successful qualitative
demonstration of an AAV2-mediated cytosine deaminase treatment, the bystander
effect was quantified as well. The activated 5-FC molecules are able to diffuse
through the plasma membrane and thus effect cells that are not transduced (</SPAN><SPAN lang="EN-US">Figure 12</SPAN><SPAN lang="EN-US">). The bystander effect was tested with
untransduced HT1080 cells, which were mixed with the CD-transduced HT1080 cells</SPAN><SPAN lang="EN-US">.</SPAN></P><DIV align="center"><TABLE class="MsoTableGrid" style="border: medium none ; border-collapse: collapse;" border="0" cellpadding="0" cellspacing="0"><TBODY><TR><TD style="padding: 0cm 5.4pt; width: 460.6pt;" valign="top" width="614"><P class="MsoCaption" style="text-align: left;" align="left"><A name="_Ref275979941"><SPAN lang="EN-US">Figure </SPAN></A><SPAN lang="EN-US">12</SPAN><SPAN lang="EN-US">: </SPAN><SPAN style="font-weight: normal;" lang="EN-US">Quantifying the bystander effect on
  HT1080 cells  5-FC: 5-fluorocytosine (53 mM)</SPAN></P></TD></TR></TBODY></TABLE></DIV><P class="MsoNormal"><SPAN lang="EN-US"> </SPAN></P><P class="MsoNormal"><SPAN lang="EN-US">The cytosine deaminase expressing cells
have an obvious effect on the viability of the non-transduced cells. As shown
in the graph we were able to demonstrate that cytosine deaminase mediated cancer
cell death is also fatal for non-transduced cells in close proximity.</SPAN></P><H3><A name="_Toc275981848"><SPAN lang="EN-US">Conclusions</SPAN></A></H3><P class="MsoNormal"><SPAN lang="EN-US">Efficient and tissue-specific tumor killing
is one major challenge in cancer therapy </SPAN><SPAN lang="EN-US">(Black et al. 1996)</SPAN><SPAN lang="EN-US">. Gene-directed enzyme
prodrug therapy (GDEPT) is based on the conversion of non-toxic substances into
toxic drugs resulting in tumor cell death. The iGEM team Freiburg_Bioware 2010
provides several functional suicide genes within the Virus Construction Kit, thus
offering a feasible and modular tool to the growing field of personalized
medicine and the iGEM community. We successfully demonstrated cancer cell death
caused by the introduction of cytosine deaminase and modified fusion genes
consisting of guanylate and thymidine kinases.</SPAN></P><P class="MsoNormal"><SPAN lang="EN-US"> To prevent systemic toxic side effects of
conventional chemotherapy, the iGEM team Freiburg_Bioware 2010 took a leap and
efficiently retargeted the viral vector for directed suicide gene delivery
towards tumor cells. Capsid engineering was successfully demonstrated by the
iGEM team Freiburg_Bioware 2010. Further details can be found under <A href="https://2010.igem.org/Team:Freiburg_Bioware/Project/Results#targeting">Results –
Targeting.</A></SPAN></P><H3><A name="_Toc275981849"><SPAN lang="EN-US">References</SPAN></A></H3><P style="text-indent: 36pt;"><SPAN style="font-size: 10pt; font-family: &quot;Calibri&quot;,&quot;sans-serif&quot;;" lang="EN-US">Ardiani, A., Sanchez-Bonilla, M. &amp;
Black, M.E., 2010. Fusion enzymes containing HSV-1 thymidine kinase mutants and
guanylate kinase enhance prodrug sensitivity in vitro and in vivo. <I>Cancer
gene therapy</I>, 17(2), 86-96. Available at:
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2808426&amp;tool=pmcentrez&amp;rendertype=abstract.</SPAN></P><P style="text-indent: 36pt;"><SPAN style="font-size: 10pt; font-family: &quot;Calibri&quot;,&quot;sans-serif&quot;;" lang="EN-US">Black, M.E. et al., 1996. Creation of
drug-specific herpes simplex virus type 1 thymidine kinase mutants for gene
therapy. <I>Proceedings of the National Academy of Sciences of the United
States of America</I>, 93(8), 3525-9. Available at:
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=39643&amp;tool=pmcentrez&amp;rendertype=abstract.</SPAN></P><P style="text-indent: 36pt;"><SPAN style="font-size: 10pt; font-family: &quot;Calibri&quot;,&quot;sans-serif&quot;;" lang="EN-US">Fuchita, M. et al., 2009. Bacterial
cytosine deaminase mutants created by molecular engineering show improved
5-fluorocytosine-mediated cell killing in vitro and in vivo. <I>Cancer research</I>,
69(11), 4791-9. Available at:
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2765227&amp;tool=pmcentrez&amp;rendertype=abstract.</SPAN></P><P style="text-indent: 36pt;"><SPAN style="font-size: 10pt; font-family: &quot;Calibri&quot;,&quot;sans-serif&quot;;" lang="EN-US">Fuchita, M. et al., 2009. Bacterial
cytosine deaminase mutants created by molecular engineering show improved
5-fluorocytosine-mediated cell killing in vitro and in vivo. <I>Cancer research</I>,
69(11), 4791-9. Available at:
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2765227&amp;tool=pmcentrez&amp;rendertype=abstract.</SPAN></P><P style="text-indent: 36pt;"><SPAN style="font-size: 10pt; font-family: &quot;Calibri&quot;,&quot;sans-serif&quot;;">Greco,
O. &amp; Dachs, G.U., 2001. </SPAN><SPAN style="font-size: 10pt; font-family: &quot;Calibri&quot;,&quot;sans-serif&quot;;" lang="EN-US">Gene directed enzyme/prodrug therapy of
cancer: historical appraisal and future prospectives. <I>Journal of cellular
physiology</I>, 187(1), 22-36. Available at:
http://www.ncbi.nlm.nih.gov/pubmed/11241346.</SPAN></P><P style="text-indent: 36pt;"><SPAN style="font-size: 10pt; font-family: &quot;Calibri&quot;,&quot;sans-serif&quot;;">Huber,
B.E. et al., 1993. </SPAN><SPAN style="font-size: 10pt; font-family: &quot;Calibri&quot;,&quot;sans-serif&quot;;" lang="EN-US">In vivo antitumor activity of 5-fluorocytosine on human
colorectal carcinoma cells genetically modified to express cytosine deaminase. <I>Cancer
research</I>, 53(19), 4619-26. Available at:
http://www.ncbi.nlm.nih.gov/pubmed/8402637.</SPAN></P><P style="text-indent: 36pt;"><SPAN style="font-size: 10pt; font-family: &quot;Calibri&quot;,&quot;sans-serif&quot;;">Huber,
B.E. et al., 1994. </SPAN><SPAN style="font-size: 10pt; font-family: &quot;Calibri&quot;,&quot;sans-serif&quot;;" lang="EN-US">Metabolism of 5-fluorocytosine to 5-fluorouracil in
human colorectal tumor cells transduced with the cytosine deaminase gene:
significant antitumor effects when only a small percentage of tumor cells
express cytosine deaminase. <I>Proceedings of the National Academy of Sciences
of the United States of America</I>, 91(17), 8302-6. Available at:
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=44594&amp;tool=pmcentrez&amp;rendertype=abstract.</SPAN></P><P style="text-indent: 36pt;"><SPAN style="font-size: 10pt; font-family: &quot;Calibri&quot;,&quot;sans-serif&quot;;" lang="EN-US">Moolten, F.L., 1986. Tumor chemosensitivity
conferred by inserted herpes thymidine kinase genes: paradigm for a prospective
cancer control strategy. <I>Cancer research</I>, 46(10), 5276-81. Available at:
http://www.ncbi.nlm.nih.gov/pubmed/3019523.</SPAN></P><P style="text-indent: 36pt;"><SPAN style="font-size: 10pt; font-family: &quot;Calibri&quot;,&quot;sans-serif&quot;;" lang="EN-US">Roche, <I>Apoptosis , Cell Death and Cell
Proliferation</I>,</SPAN></P><P style="text-indent: 36pt;"><SPAN style="font-size: 10pt; font-family: &quot;Calibri&quot;,&quot;sans-serif&quot;;" lang="EN-US">Willmon, C.L., Krabbenhoft, E. &amp; Black,
M.E., 2006. A guanylate kinase/HSV-1 thymidine kinase fusion protein enhances
prodrug-mediated cell killing. <I>Gene therapy</I>, 13(17), 1309-12. Available
at: http://www.ncbi.nlm.nih.gov/pubmed/16810197.</SPAN></P><P><SPAN lang="EN-US"> </SPAN></P></DIV><DIV class="printfooter">
Retrieved from &quot;<A href="http://2010.igem.org/Team:Freiburg_Bioware/Project/Results/Arming">http://2010.igem.org/Team:Freiburg_Bioware/Project/Results/Arming</A>&quot;</DIV></DIV></DIV><DIV id="footer-box" class="noprint"><DIV id="footer"><UL id="f-list"><LI id="t-recentchanges"><A href="/Special:RecentChanges" title="Recent changes">Recent changes</A></LI><LI id="t-whatlinkshere"><A href="/Special:WhatLinksHere/Team:Freiburg_Bioware/Project/Results/Arming" title="List of all wiki pages that link here [j]" accesskey="j">What links here</A></LI><LI id="t-recentchangeslinked"><A href="/Special:RecentChangesLinked/Team:Freiburg_Bioware/Project/Results/Arming" title="Recent changes in pages linked from this page [k]" accesskey="k">Related changes</A></LI><LI id="t-specialpages"><A href="/Special:SpecialPages" title="List of all special pages [q]" accesskey="q">Special pages</A></LI><LI><A href="/Special:Preferences">My preferences</A></LI></UL></DIV><DIV id="footer"><UL id="f-list"><LI id="t-print"><A href="/wiki/index.php?title=Team:Freiburg_Bioware/Project/Results/Arming&amp;printable=yes" title="Printable version of this page [p]" accesskey="p">Printable version</A></LI><LI id="t-permalink"><A href="/wiki/index.php?title=Team:Freiburg_Bioware/Project/Results/Arming&amp;oldid=206805" title="Permanent link to this revision of the page">Permanent link</A></LI><LI id="privacy"><A href="/2010.igem.org:Privacy_policy" title="2010.igem.org:Privacy policy">Privacy policy</A></LI><LI id="disclaimer"><A href="/2010.igem.org:General_disclaimer" title="2010.igem.org:General disclaimer">Disclaimers</A></LI></UL></DIV></DIV></DIV></BODY></HTML>